Skip to main content

Table 1 Sample demographic and clinical characteristics. The total sample included 465 participants from the National Alzheimer’s Coordinating Uniform Data Set. All participants were diagnosed with normal cognition at the baseline study visit. The final analytic sample included those who remained stable with normal cognition and those who converted to MCI due to AD or AD dementia (n = 56). APOE data were missing for six participants

From: Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer’s Coordinating Center Uniform Data Set

VariableMean (SD) or n (%)Range
Age at baseline MRI visit68.9 (11.8)45–100
Total length of follow-up (years)5.10 (2.14)1.45–11.67
Total number of follow-up visits4.62 (1.91)2–10
Sex146 (31.4%) male 
Years of education15.37 (3.41)1–25
Ethnicity86.9% white, 10.3% AA, 2.8% other 
APOE ε4 carrier status162 (35.3%) carriers 
Systolic blood pressure132 (18.8)78–198
History of hypertension200 (43.0%) 
History of diabetes80 (17.2%) 
History of hypercholesterolemia224 (48.2%) 
WMH volume at baseline (cm3)4.70 (8.71)0–61.24
Natural log of WMH at baseline0.45 (1.52)− 2.30–4.12
Diagnosis at final study visit
 Normal cognition417 (89.7%) 
 MCI22 (4.7%) 
 Dementia26 (5.6%) 
CDR Sum of Boxes at final study visit0.55 (1.83)0–18
  1. Abbreviations: beta-amyloid, CDR Clinical Dementia Rating scale, MCI mild cognitive impairment, MRI magnetic resonance imaging, WMH white matter hyperintensities